Martin Kaszubowski, MD
Gastroenterology · Anchorage, AKNPI 1518016187
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 30 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by AbbVie at 46.4% of the total. Reporting peaked in 2020 at $164 and has fallen 69.2% since, to $50 in 2024.
Across 30 payments — averaging $21.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$300
- Pfizer$156
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$49
- UCB, Inc.$36
- Sanofi$30
- Boston Scientific$24
- plus $52 from 3 others
What the payments were for
- Food & beverage$646100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 16 | $300 |
| Pfizer | 4 | $156 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $49 |
| UCB, Inc. | 2 | $36 |
| Sanofi | 1 | $30 |
| Boston Scientific | 1 | $24 |
| Regeneron Healthcare Solutions, Inc. | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Bristol Myers Squibb | 1 | $13 |
How this compares
$646 in reported general payments places this provider in the 55th percentile of 23 gastroenterology providers in Alaska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg | 50 | $1,200 |
| Pantoprazole Sodium | 38 | $854 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 11 | $191 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Anchorage
- Daryl McClendonAnchorage$6K
- Brian SweeneyAnchorage$6K
- Austin NelsonAnchorage$5K
- Jeffery MolloyAnchorage$5K
- Michelle RandolphAnchorage$1K
- Kavya Kelagere MayigegowdaAnchorage$710
- Ronald BoisenAnchorage$555
- Geronimo SahagunAnchorage$527
- Saket AmbashtAnchorage$521
- Praveen RoyAnchorage$517
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.